Diasorin S.p.a. · MIL:DIA
Diasorin — Q2 2026 Earnings Presentation
23 slides from Diasorin's earnings presentation, Jul 31, 2026
Slide 1: H1 & Q2 2026 Results
XY Oiasorin H1 & Q2 2026 RESULTS July 31, 2026
Slide 2: Disclaimer
DISCLAIMER In General. This disclaimer applies to this presentation and any oral No distribution of this Presentation. This Presentation is being furnished to comments of any person presenting it. This document, taken together you solely for your information and may not be reproduced, in whole or in
Slide 3: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS This document contains forward-looking statements that are based on current expectations, estimates, forecasts and projections about the industries in which Diasorin operates and the beliefs and assumptions of the management of Diasorin. In addition, the management of Dias
Slide 4: Business Highlights
BUSINESS HIGHLIGHTS +) Diasorin
Slide 5: Business highlights timeline Jan-Jun 2026
Jan Feb Mar Apr May Jun 2026 2026 2026 2026 2026 2026 LIAISON Delta Hepatitis QuantiFERON-TB Gold U.S. Market Plus II U.S. Market Authorization request Commercial Launch LIAISON PLEX Gastro- LIAISON NES Group A LIAISON NES Group A intestinal Flex Assay Strep LIAISON NES Strep U.S. Market U.S. Market
Slide 6: Financial Highlights
FINANCIAL HIGHLIGHTS +) Diasorin
Slide 7: Q2'26 & H1'26 Revenue Variances at Constant Exchange Rates
Q2’26 & H1’26 Revenue Variances at Constant Exchange Rates 2025 Q2’26 Group revenues (figures in €/million) H1’26 Group revenues (figures in €/million) Note: Absolute values at current exchange rates. YoY variations are presented using 2025 constant exchange rates. Both absolute figures and percenta
Slide 8: Q2'26 & H1'26 Immunodiagnostic Revenue Variances
Q2’26 & H1’26 Immunodiagnostic Revenue Variances At Constant Exchange Rates 2025 Q2’26 revenues (figures in €/million) H1’26 revenues (figures in €/million) Base Business (ex-China) in Q2’26: China: • Delivered results in line with expectations, benefiting from the gradual normalization of the facto
Slide 9: Q2'26 & H1'26 Molecular Diagnostic Revenue Variances
Q2’26 & H1’26 Molecular Diagnostic Revenue Variances At Constant Exchange Rates 2025 Q2’26 revenues (figures in €/million) H1’26 revenues (figures in €/million) Lowplex Multiplex Lowplex Multiplex Automated multiplexing: LIAISON MDX targeted: • Business impacted by a soft tail of flu season • Growth
Slide 10: Automated Multiplexing: LIAISON PLEX
Automated Multiplexing: LIAISON PLEX LIAISON PLEX CUSTOMERS: ca. 150 (65% flex vs. 35% fixed) BY NUMBER OF CUSTOMERS BY REVENUE CONTRIBUTION • 10% commercial labs • 30% commercial labs • 90% hospital labs • 70% hospital labs LIAISON PLEX COMMERCIAL LAUNCH UPDATE: • Commercial team fully established
Slide 11: Q2'26 & H1'26 LTG Revenue Variances
Q2’26 & H1’26 LTG Revenue Variances At Constant Exchange Rates 2025 Q2’26 revenues (figures in €/million) H1’26 revenues (figures in €/million) Life Science clients: • Initial signs of recovery from the unfavorable market conditions which impacted performance in 2025 Diagnostics clients: • Unfavorab
Slide 12: Q2'26 & H1'26 Profitability Profile
Q2’26 & H1’26 Profitability Profile Net Revenues and Adj. EBITDA data @ current exchange rates; Adj. EBITDA Margin @ constant exchange rates. 35% 33% 306 315 108 105 Net Revenues In H1 2026, Adjusted1 EBITDA2 Margin was equal to 32% @ CER, mainly due to Volume Based Procurement (VBP) impact on price
Slide 13: FY 2026 Company Guidance and 2026 Outlook
FY 2026 COMPANY GUIDANCE AND 2026 OUTLOOK +) Diasorin
Slide 14: FY'26 Guidance Confirmed
FY’26 Guidance Confirmed FY’26 GUIDANCE (@CER 2025) CERPY Spot EUR/USD FX: 1.05 Avg. Expected 2026 EUR/USD FX: 1.16 (Source: Bloomberg) as of July 30, 2026 1 cent of difference between EUR and USD over 12 months has an impact on: • FY Revenue of ca. €/mln 6-8 • FY EBITDA of ca. €/mln 2-3 1 With refe
Slide 15: FY'26 Top Line Guidance
FY’26 Top Line Guidance @CER2025 Revenue Guidance FY’26 Between +5% and +6% 1,195 €/mln • LTG: diagnostic customers are expected to grow at a LSD-to-MSD% rate, +LSD% offsetting the continued weakness in the Life Science business. LTG 165 €/mln • Molecular Diagnostics: growth driven by the launch of
Slide 16: FY'26 Growth Trajectory by Quarter
FY’26 Growth Trajectory by Quarter 1Q26 2Q26 3Q26 4Q26 • Immunodiagnostics: steady growth across different quarters in FY’26 as a result of the unique specialty menu and the hospital strategy, partially compensated by the normalization of volumes in Europe, with the exception of some tough compariso
Slide 17: Financial Schemes
FINANCIAL SCHEMES +) Diasorin
Slide 18: Income Statement
Income Statement Q2 Change H1 Change Amounts in millions of euros 2025 2026 amount % 2025 2026 amount % Net Revenues 306 315 +9 +3% 619 602 -18 -3% Cost of sales (105) (111) -6 +6% (213) (212) +1 -1% Gross profit 201 204 +2 +1% 406 389 -17 -4% 66% 65% -105 bps 66% 65% -82 bps Sales and marketing exp
Slide 19: Balance Sheet
Balance Sheet Amounts in millions of euros 12/31/2025 06/30/2026 Change Goodwill and intangibles assets 1,790 1,827 +38 Property, plant and equipment 256 272 +16 Other non-current assets 42 43 +1 Net working capital 325 384 +58 Other non-current liabilities (257) (266) -10 Net Invested Capital 2,157
Slide 20: Cash Flow Statement
Cash Flow Statement Q2 H1 Amounts in millions of euros 2025 2026 2025 2026 Cash and cash equivalents at the beginning of the period 365 201 344 166 Cash provided by operating activities 74 51 145 109 Cash provided/(used) in investing activities (35) (29) (28) (13) Cash provided/(used) in financing a
Slide 21: June 2026 Reconciliation to Consolidated Financial Statements
June 2026 Reconciliation to Consolidated Financial Statements Amounts in millions of euros Gross Profit EBITDA EBIT Net Result Financial Statements Measures 389 188 125 84 % on Revenues 65% 31% 21% 14% Adjustments “One-off” costs related to non recurring events 1 6 5 5 Depreciation of Luminex intang
Slide 22: June 2025 Reconciliation to Consolidated Financial Statements
June 2025 Reconciliation to Consolidated Financial Statements Amounts in millions of euros Gross Profit EBITDA EBIT Net Result Financial Statements Measures 406 204 138 99 % on Revenues 66% 33% 22% 16% Adjustments “One-off” costs related to non recurring events 2 12 12 12 Depreciation of Luminex int
Slide 23: Slide 23